Cell Line Development
Stable cell line establishment and clone selection for antibody and antibody-based modalities.
SERVICES · CDMO
Contract Development & Manufacturing
End-to-end antibody contract development and manufacturing — from cell line development to GMP clinical supply — backed by two decades of in-house antibody drug development.
Scale
50 L + 200 L GMP
Scope
Cell line → GMP supply
Clinical
Phase 1 supply-ready
Site
Single-site, New Taipei
01 — Overview
Antibody CDMO from an Integrated Drug-Development Organization
GlycoNex provides contract development and manufacturing (CDMO) services for antibody and antibody-based therapeutics, drawing on the same integrated organization that develops its own clinical-stage ADCs and biosimilars. Capabilities span cell line development; upstream, midstream, and downstream process development and optimization; scale-up; GMP manufacturing; and technology transfer. Manufacturing is supported by GMP-compliant antibody production at 50-liter intermediate and 200-liter production scale at the company's New Taipei City facility, capable of supplying Phase 1 clinical material. Contract development and manufacturing services form a deliberate part of GlycoNex's business model, providing a recurring revenue stream alongside its proprietary drug development programs.
02 — Capabilities
Services Across the Antibody Development Workflow
Process Development & Scale-Up
Upstream, midstream, and downstream process development, optimization, and scale-up.
GMP Manufacturing
GMP-compliant antibody production at 50 L and 200 L scale, supporting Phase 1 clinical supply.
Technology Transfer
Structured technology transfer and project management across the development-to-manufacturing workflow.
03 — Integrated Glycan Analytical Platform
Analytical Depth Tuned for Antibody Glycoforms
GlycoNex's integrated glycan analytical platform combines liquid chromatography, ion chromatography, and mass spectrometry with the recognition capability of its GlycoSH antibody collection. The platform characterizes critical quality attributes including N-glycan profiles, molecular weight and primary structure, post-translational modifications, and glycoform composition and batch consistency. This analytical depth supports both novel anti-glycan therapeutic development and biosimilar programs, where glycoform composition and consistency are critical quality attributes for comparability assessment, process control, and batch monitoring.
04 — Why GlycoNex
What Sets the CDMO Apart
Vertically integrated
A single-site organization spanning antibody discovery, process development, GMP production, and quality management.
Backed by an active pipeline
The teams supporting external programs also develop GlycoNex's own clinical-stage ADCs and biosimilars.
Glycan & biosimilar analytical depth
Specialized glycan characterization supporting comparability and quality for complex antibody programs.
Demonstrated track record
Contract programs delivered for external biotechnology partners, including a published neurodegenerative-disease antibody collaboration.
05 — Selected Engagement
Recent Contract Program
In December 2025, GlycoNex entered a contract development and manufacturing agreement with Change Cure, a spin-off from Institute of Science Tokyo, for CC001 — an HMGB1-targeted antibody program for frontotemporal lobar degeneration (FTLD), a neurodegenerative indication. GlycoNex also provides contract services to additional biotechnology companies in Taiwan whose engagements remain confidential.